PharmacoEconomics

, Volume 23, Issue 3, pp 219–226

Penny and pound wise

Pharmacoeconomics from a governmental perspective
  • Mike F. van Oostenbruggen
  • Ronald B. Jansen
  • Katja Mur
  • Huib Kooijman
Current Opinion

Abstract

Because of growing pressure on the healthcare budget in The Netherlands, appropriate justification of current expenditures and future investments in public healthcare are becoming increasingly important. Therefore, the Dutch Ministry of Health, Welfare and Sport is expanding its use of pharmacoeconomic evaluation in informed reimbursement decision-making of new pharmaceuticals. Since June 2002, pharmaceutical companies have been invited to submit a pharmacoeconomic dossier with their reimbursement applications of innovative drugs. As of January 2005 submission of a pharmacoeconomic dossier is mandatory for all drugs claiming to have therapeutic value.

Currently, several European governmental and non-governmental organisations are making efforts to harmonise pharmacoeconomic research guidelines at the EU level. Ultimately, this may facilitate a more efficient way of conducting pharmacoeconomic research and encourage the use of pharmacoeconomic data by national assessment agencies and governments.

It is anticipated that international pharmaceutical companies will increasingly invest in pharmacoeconomics while government staff will become more experienced in appraising the dossiers, thus resulting in an upward momentum in the quality and usability of pharmacoeconomic data.

From the Dutch government’s perspective, the use of pharmacoeconomic evaluation in reimbursement decision-making should offer a true opportunity for pharmaceutical companies to present the added value for money of new drugs. Using pharmacoeconomic data, costs, benefits and effects of pharmaceuticals are increasingly being considered from a societal perspective, thus going beyond the sole consideration of the impact on the pharmaceutical budget.

References

  1. 1.
    Ministerie van Volksgezondheid Welzijn en Sport. Medicines policy in The Netherlands: International Publication Series health, Welfare and Sport no. 15. The Hague: Ministry of Health, Welfare and Sport, 2003Google Scholar
  2. 2.
    Kostenbeheersing in de zorg, Kamerstuk 24124 nr 39. The Hague: Tweede Kamer der Staten-Generaal, 1996Google Scholar
  3. 3.
    Vaststelling van de begroting van de uitgaven en de ontvangsten van het Ministerie van Volksgezondheid, Welzijn en Sport (XVI) voor het jaar 1997, Kamerstuk 25000 xvi nr 71. The Hague: Tweede Kamer der Staten-Generaal, 1997Google Scholar
  4. 4.
    Richtlijn voor farmaco-economisch onderzoek, Brief van de minister van Volksgezondheid, Welzijn en Sport aan de voorzitter van de Ziekenfondsraad. The Hague, Ministry of Health, Welfare and Sport, 1997Google Scholar
  5. 5.
    Riteco JA, de Heij UM, Van Luijn JCF, et al. Dutch guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen, 1999Google Scholar
  6. 6.
    Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20 (7): 443–54PubMedCrossRefGoogle Scholar
  7. 7.
    Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. Amstelveen: College voor Zorgverzekeringen, 2004Google Scholar
  8. 8.
    College voor zorgverzekeringen, CVZ Farmaco-economisch rapportpharmacoeconomic reports Thyrogen®. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nl/resources/cfh-0209thyrogenfertcm13-1771.pdf [Accessed 2004 Dec 17]
  9. 9.
    van Luijn JCF. CFH-Rapport risperidone depot (Risperdal Consta®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nUresources/cfh03-03risperidondepot-FEtcm132195.pdf [Accessed 2004 Dec 17]Google Scholar
  10. 10.
    Toenders WGM. CFH-Rapport clopidogrel (Plavix®) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-06%20clopidogrel%20FER_tcml3-6750.pdf [Accessed 2004 Dec 17]Google Scholar
  11. 11.
    Toenders WGM. CFH-Rapport vardenafil (Levitra(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh03-20%20vardenafil%20FER_tcml3-6806.pdf [Accessed 2004 Dec 17]Google Scholar
  12. 12.
    Toenders WGM. CFH-Rapport eplerone (Inspra(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.evz.nl/resources/cfh04-26%20eplerenon%20FER_tcm13-9527.pdf [Accessed 2004 Dec 17]Google Scholar
  13. 13.
    Toenders WGM. CFH-Rapport pimecrolimus (Plavix(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-01%20pimecrolimus%20FER_tcm13-6084.pdf [Accessed 2004 Dec 17]Google Scholar
  14. 14.
    Toenders WGM. CFH-Rapport Asi-colon (Oncovax(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.cvz.nl/resources/cfh04-oncovax%20FERtern13-6527.pdf [Accessed 2004 Dec 17]Google Scholar
  15. 15.
    Toenders WGM. CFH-Rapport omega-3-vetzuren (Omacor(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2004 [online]. Available from URL: http://www.evz.nl/ resources/cfh04-13-omega-3-vetzuren-FER_tcml3-7841.pdf [Accessed 2004 Dec 17]Google Scholar
  16. 16.
    van Luijn JCF. CFH-Rapport risperidone depot (Risperdal Consta(D) Bijlage FE rapport. Amstelveen: College voor Zorgverzekeringen, 2003 [online]. Available from URL: http://www.cvz.nUresources/cfh03-03risperidondepot-FEtcm132195.pdf [Accessed 2004 Dec 17]Google Scholar
  17. 17.
    Hill SR, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16: 2116–21PubMedCrossRefGoogle Scholar
  18. 18.
    A proposal for methodological guidelines for economic evaluation of pharmaceuticals. Brussels: Belgian Society for Pharmacoepidemiology, 1995Google Scholar
  19. 19.
    Amtliche Verlautbarungen der osterreichischen Sozialversicherung; Verfahrensordnung (no 100) zur Herausgabe des Heilmittelverzeichnisses. Vienna: Der Hauptverband der 6sterreichischen Sozialversicherungstrager, 2003Google Scholar
  20. 20.
    Baltic guidelines for economic evaluation of pharmaceuticals. Health authorities from the Baltic countries, 2002 [online]. Available from URL: http://www.zea.gov.ly/does/new2002/doc24-l.pdf [Accessed 2004 Aug 8]
  21. 21.
    General guidelines for economic evaluation from the Pharmaceutical Benefits Board LNFAR. Solna: Swedish Pharmaceutical Benefits Board, 2003 [online]. Available from URL: http://www.Ifn.se/upload/English/ENGlfnar2003-eng.pdf [Accessed 2004 Aug 8]
  22. 22.
    Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Norwegian Medicines Control Authority, 2000 [online]. Available from URL: http://www.legemiddelverket.no/eng/reg/pharmacoeconomic-analysis-guidelines.htm [Accessed 2004 Aug 8]
  23. 23.
    Dickson M, Hurst J, Jacobzone S. OECD health working papers no. 4 survey of pharmacoeconomic assessment activity in eleven countries. France: OECD, 2003 [online]. Available from URL: http://www.oeed.org/dataoeed/27/25/2955828.pdf [Accessed 2004 Aug 8]CrossRefGoogle Scholar
  24. 24.
    Bemkover JD, Corey R. Effective utilization of pharmacoeconomics for decision makers. Dis Manage Health Outcomes 2002; 10 (2): 75–80CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Mike F. van Oostenbruggen
    • 1
  • Ronald B. Jansen
    • 1
  • Katja Mur
    • 1
  • Huib Kooijman
    • 2
  1. 1.Department of Pharmaceutical Affairs and Medical TechnologyMinistry of Health, Welfare and SportThe HagueThe Netherlands
  2. 2.PharMerit BVRotterdamThe Netherlands

Personalised recommendations